Richard W E Clarkson
Overview
Explore the profile of Richard W E Clarkson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turnham D, Mullen M, Bullock N, Gilroy K, Richards A, Patel R, et al.
Cells
. 2024 Apr;
13(8.
PMID: 38667288
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and...
2.
Turnham D, Smith H, Clarkson R
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255248
The NF-κB co-factor Bcl3 is a proto-oncogene that promotes breast cancer proliferation, metastasis and therapeutic resistance, yet its role in breast cancer cell survival is unclear. Here, we sought to...
3.
Davies J, Marlow G, Uusi-Kerttula H, Seaton G, Piggott L, Badder L, et al.
Viruses
. 2021 Jun;
13(5).
PMID: 34066836
We previously developed a refined, tumor-selective adenovirus, Ad5-A20, harboring tropism ablating mutations in each major capsid protein, to ablate all native means of infection. We incorporated a 20-mer peptide (A20)...
4.
Soukupova J, Bordoni C, Turnham D, Yang W, Seaton G, Gruca A, et al.
Mol Cancer Ther
. 2021 Mar;
20(5):775-786.
PMID: 33649105
The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options...
5.
Turnham D, Yang W, Davies J, Varnava A, Ridley A, Conlan R, et al.
Carcinogenesis
. 2020 Jan;
41(10):1432-1443.
PMID: 31957805
A key challenge in the implementation of anti-metastatics as cancer therapies is the multi-modal nature of cell migration, which allows tumour cells to evade the targeted inhibition of specific cell...
6.
Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller W, et al.
Cancer Res
. 2012 Nov;
73(2):745-55.
PMID: 23149915
Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tumors. Studies in cell lines suggest that its oncogenic effects are mediated through the induction of proliferation and inhibition of...
7.
Knight J, Hallett A, Brancale A, Paisey S, Clarkson R, Edwards P
Chembiochem
. 2011 Oct;
12(17):2692-8.
PMID: 21998043
AMD3100 is a potent and selective antagonist of the CXCR4 receptor; it has been shown to block the route of entry of HIV into host T-cells. This compound and its...
8.
Piggott L, Omidvar N, Marti Perez S, French R, Eberl M, Clarkson R
Breast Cancer Res
. 2011 Sep;
13(5):R88.
PMID: 21914219
Introduction: It is postulated that breast cancer stem cells (bCSCs) mediate disease recurrence and drive formation of distant metastases - the principal cause of mortality in breast cancer patients. Therapeutic...
9.
Kreuzaler P, Staniszewska A, Li W, Omidvar N, Kedjouar B, Turkson J, et al.
Nat Cell Biol
. 2011 Feb;
13(3):303-9.
PMID: 21336304
It is well established that lysosomes play an active role during the execution of cell death. A range of stimuli can lead to lysosomal membrane permeabilization (LMP), thus inducing programmed...
10.
Tiffen P, Omidvar N, Marquez-Almuina N, Croston D, Watson C, Clarkson R
Mol Endocrinol
. 2008 Oct;
22(12):2677-88.
PMID: 18927239
Recent studies in breast cancer cell lines have shown that oncostatin M (OSM) not only inhibits proliferation but also promotes cell detachment and enhances cell motility. In this study, we...